McNairn Adrian J, Gerton Jennifer L
Stowers Institute for Medical Research, Kansas City, MO 64110, USA.
Mutat Res. 2008 Dec 1;647(1-2):103-11. doi: 10.1016/j.mrfmmm.2008.08.010. Epub 2008 Aug 22.
Over 75 years ago, two human genetic disorders were initially described and named for their founding physicians: Cornelia de Lange (CdLS) and Roberts syndrome (RBS)/SC Phocomelia (SC). In the past 4 years, genetic studies of patients have revealed the primary genes involved in these disorders are the essential, evolutionarily conserved components of the cohesin pathway. This pathway serves to facilitate cohesion between replicated sister chromatids, thereby enabling proper chromosome segregation. As a result of these findings, these disorders now represent a novel class of human genetic disorders known as cohesinopathies. Over 60% of CdLS patients examined have de novo mutations in either: SCC2/NIPBL, SMC1, or SMC3, whereas the causative gene in Roberts syndrome and SC Phocomelia has been identified as ESCO2. Now modern genetic, biochemical, and cell biological approaches may be applied to determine the underlying mechanism of these genetic disorders.
75 多年前,两种人类遗传疾病首次被描述,并以其发现医生的名字命名:科妮莉亚·德朗格综合征(CdLS)和罗伯茨综合征(RBS)/短肢畸形(SC)。在过去的 4 年里,对患者的基因研究表明,这些疾病所涉及的主要基因是黏连蛋白途径中必不可少的、在进化上保守的成分。该途径有助于促进复制后的姐妹染色单体之间的黏连,从而实现正确的染色体分离。这些发现使得这些疾病现在代表了一类新的人类遗传疾病,即黏连蛋白病。超过 60%接受检查的 CdLS 患者在以下基因中存在新发突变:SCC2/NIPBL、SMC1 或 SMC3,而罗伯茨综合征和短肢畸形的致病基因已被确定为 ESCO2。现在,可以应用现代遗传学、生物化学和细胞生物学方法来确定这些遗传疾病的潜在机制。